Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Alkeran)
11,668 results
  • Liposome-Encapsulated Melphalan Exhibits Potent Antimyeloma Activity and Reduced Toxicity. [Journal Article]
    ACS Omega. 2023 Jan 10; 8(1):1693-1701.Lin Z, Chu B, … Zheng Y
  • Multiple myeloma (MM), a plasma cell cancer in bone marrow, remains an incurable disease. Melphalan, an alkylating agent, is a conventional anticancer drug that is still widely used for MM treatment in clinics. However, melphalan-induced organ toxicity and side effects are common. In this study, we loaded melphalan into a liposomal capsule and constituted liposomal melphalan (liposomal MEL). Lipo…
  • Autologous stem cell transplantation in multiple myeloma patients with renal impairment. [Journal Article]
    Ann Hematol. 2023 Jan 12 [Online ahead of print]Zhai Y, Yan L, … Wu D
  • Renal impairment (RI) used to exclude multiple myeloma (MM) patients from autologous stem cell transplantation (ASCT) for safety concerns. Here, we retrospectively reviewed 34 consecutively transplanted patients with creatinine clearance < 60 ml/min at ASCT in recent 5 years at our institution. Busulfan/cyclophosphamide and high-dose melphalan were both employed as conditioning regimens. We found…
  • Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures. [Journal Article]
    Blood. 2023 Jan 10 [Online ahead of print]Diamond BT, Ziccheddu B, … Maura F
  • Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Pre-leukemic clones (i.e., clonal hematopoiesis; CH) are detectable years before the development of these aggressive malignancies, though the genomic events leading to transformation and expansion are not well-defined. Here, leveraging dist…
  • High-Dose Melphalan Treatment Significantly Increases Mutational Burden at Relapse in Multiple Myeloma. [Journal Article]
    Blood. 2023 Jan 05 [Online ahead of print]Samur MK, Roncador M, … Munshi NC
  • High Dose Melphalan (HDM) improves progression free survival (PFS) in multiple myeloma (MM), yet melphalan is a DNA damaging alkylating agent, so we assessed its mutational effect on surviving myeloma cells by analyzing paired MM samples collected at diagnosis and relapse from the IFM 2009 study. We performed deep whole genome sequencing on 68 patients, 43 treated with RVD (lenalidomide, bortezom…
  • Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages. [Journal Article]
    Emerg Microbes Infect. 2023 Dec; 12(1):e2161422.Xia H, Yeung J, … Shi PY
  • The rapid evolution of SARS-CoV-2 Omicron sublineages mandates a better understanding of viral replication and cross-neutralization among these sublineages. Here we used K18-hACE2 mice and primary human airway cultures to examine the viral fitness and antigenic relationship among Omicron sublineages. In both K18-hACE2 mice and human airway cultures, Omicron sublineages exhibited a replication ord…
  • [Anesthesiological and postinterventional management in percutaneous hepatic melphalan perfusion (chemosaturation)]. [Review]
    Anaesthesiologie. 2022 Dec 07 [Online ahead of print]Kliem P, Ebel S, … Struck MF
  • Percutaneous hepatic melphalan perfusion (PHMP) is a last-line treatment of inoperable primary or secondary liver tumors. Selective perfusion and saturation (chemosaturation) of the liver with the chemotherapeutic agent melphalan is performed via catheterization of the hepatic artery without affecting the rest of the body with its cytotoxic properties. Using an extracorporeal circulation and ball…
New Search Next